Pfizer Inc. (NYSE:PFE) Shares Acquired by Retirement Planning Co of New England Inc.

Retirement Planning Co of New England Inc. increased its position in Pfizer Inc. (NYSE:PFE) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,695 shares of the biopharmaceutical company’s stock after buying an additional 779 shares during the quarter. Retirement Planning Co of New England Inc.’s holdings in Pfizer were worth $655,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Mystic Asset Management Inc. lifted its holdings in shares of Pfizer by 126.6% in the fourth quarter. Mystic Asset Management Inc. now owns 174,006 shares of the biopharmaceutical company’s stock valued at $4,616,000 after buying an additional 97,231 shares during the period. Leelyn Smith LLC lifted its holdings in shares of Pfizer by 6.4% in the fourth quarter. Leelyn Smith LLC now owns 87,767 shares of the biopharmaceutical company’s stock valued at $2,328,000 after buying an additional 5,311 shares during the period. RD Lewis Holdings Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at $617,000. Axxcess Wealth Management LLC lifted its holdings in shares of Pfizer by 0.9% in the fourth quarter. Axxcess Wealth Management LLC now owns 194,907 shares of the biopharmaceutical company’s stock valued at $5,171,000 after buying an additional 1,696 shares during the period. Finally, Flagship Wealth Advisors LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $420,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.3 %

NYSE:PFE opened at $26.07 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The business’s fifty day moving average price is $26.22 and its 200 day moving average price is $27.10. The firm has a market capitalization of $147.72 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The business’s revenue was up 24.7% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PFE shares. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Wednesday, March 12th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.